abrdn Life Sciences Investors Shares of Beneficial Interest

abrdn Life Sciences Investors Shares of Beneficial Interest

Share · US87911K1007 · HQL (XNYS)
Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of abrdn Life Sciences Investors Shares of Beneficial Interest
No Price
29.04.2026 18:37
Current Prices from abrdn Life Sciences Investors Shares of Beneficial Interest
ExchangeTickerCurrencyLast TradePriceDaily Change
XNYS: NYSE
NYSE
HQL
USD
29.04.2026 18:37
17,35 USD
-0,18 USD
-1,03 %
IEXG: IEX
IEX
HQL
USD
29.04.2026 18:32
17,36 USD
-0,17 USD
-0,97 %
Share Float & Liquidity
Free Float 89,71 %
Shares Float 27,28 M
Shares Outstanding 30,41 M
Company Profile for abrdn Life Sciences Investors Shares of Beneficial Interest Share
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

Company Data

Name abrdn Life Sciences Investors Shares of Beneficial Interest
Company Tekla Life Sciences Investors
Symbol HQL
Website https://www.teklacap.com/hql.html
Primary Exchange XNYS NYSE
ISIN US87911K1007
Asset Class Share
Sector Financial Services
Industry Asset Management
CEO Daniel R. Omstead M.S,
Market Capitalization 533 Mio
Country United States of America
Currency USD
Employees -
Address 100 Federal Street, 02110 Philadelphia
IPO Date 1992-05-01
Dividends from 'abrdn Life Sciences Investors Shares of Beneficial Interest'
Ex-Date Dividend per Share
20.02.2026 0,56 USD
21.11.2025 0,50 USD
22.08.2025 0,42 USD
22.05.2025 0,43 USD
21.02.2025 0,47 USD
21.11.2024 0,50 USD
23.08.2024 0,49 USD
22.05.2024 0,48 USD
21.02.2024 0,39 USD
21.11.2023 0,30 USD

Ticker Symbols

Name Symbol
NYSE HQL
More Shares
Investors who hold abrdn Life Sciences Investors Shares of Beneficial Interest also have the following shares in their portfolio:
Opus-Charter.Iss. S.A.Cpmt 170 Tracker B08.10.29 CLO Note
Opus-Charter.Iss. S.A.Cpmt 170 Tracker B08.10.29 CLO Note Unbekannt
TRIPLE POINT VCT 2011 PLC - VENTURE ORD 1P
TRIPLE POINT VCT 2011 PLC - VENTURE ORD 1P Fund